ライフサイエンスコーパス: phentolamine

1 by serotonin were also partially reduced by phentolamine.

2 cking alpha-adrenoreceptors with intravenous phentolamine.

3 of alpha-adrenoreceptor blockade produced by phentolamine.

4 ICI 118,551 but not by the alpha-antagonist phentolamine.

5 o control for any beta-adrenergic effects of phentolamine.

6 rimethaphan also had a depressor response to phentolamine.

7 , and the imidazoline compounds efaroxan and phentolamine.

8 s blocked by the alpha-adrenergic antagonist phentolamine.

9 post-exercise ischaemia after bretylium and phentolamine.

10 of 50, 60, 70, and 80 mm Hg before and after phentolamine (0.5 mg/kg, intravenously, n=7) and propran

11 sympathetic nervous system, rats were given phentolamine (1 mg kg-1, i.v.).

12 (5 mg/kg) and propranolol (1 mg/kg), but not phentolamine (1 mg/kg), significantly antagonized the in

13 uated by prior intravenous administration of phentolamine (1 mg/kg).

14 Topical phentolamine (1 mum) had no effect on resting diameter b

15 n YM, blockade of alpha-adrenoreceptors with phentolamine (1 mum) restored ROV in OM.

16 Tetrodotoxin (TTX, 1 mumol/L), phentolamine (1 mumol/L), prazosin (0.1 mumol/L), or 6-h

17 over study, subjects were given IV saline or phentolamine, 1 mg/kg over 20 min.

18 y antagonized by either the alpha-antagonist phentolamine (10 microM) or the alpha2-antagonist idazox

19 ation), or isoproterenol (1 micromol/L) plus phentolamine (10 micromol/L, selective beta-adrenergic s

20 0(-3) mol/L), propranolol (10(-5) mol/L), or phentolamine (10(-5) mol/L) did not significantly alter

21 Bath application of the octopaminergic drugs phentolamine (10(-6) M), epinastine (10(-6) M) or DCDM (

22 uscle force production, inhibiting alphaARs (phentolamine; 10(-6) m) improved ROV in FA and 1A of old

23 effects of LCN stimulation were reversed by phentolamine (3 microM) or yohimbine (100 nM), but not p

24 Pretreatment with phentolamine (30 microgram/5 microliter, icv, n=8), praz

25 s noradrenaline release) was abolished after phentolamine (40 +/- 3 vs. 2 +/- 1 %; before vs. after b

26 (0.5 mg/kg), but not by the alpha-antagonist phentolamine (5 mg/kg).

27 Phentolamine (75 mg/min) produced vasodilation in obese

28 ne (an alpha(2)-adrenoceptor antagonist) and phentolamine (a non-selective alpha-adrenoceptor antagon

29 at 8 weeks of age were treated with saline, phentolamine, a nonselective alpha-adrenergic receptor a

30 The alpha-adrenoreceptor antagonist phentolamine abolished NE inhibition of eEPSCs.

31 amics in the control limb were unaffected by phentolamine administration in the contralateral (experi

32 Phentolamine (alpha-adrenergic receptor (alpha-Ad) antag

33 Phentolamine (alpha-adrenergic receptor blocker) not onl

34 ividual (prazosin, rauwolscine) or combined (phentolamine) alpha-receptor inhibition.

35 Phentolamine also unmasked the vasodilator AII actions a

36 etylium (to block noradrenaline release) and phentolamine (an alpha-adrenergic antagonist), profound

37 e to catecholamine derived vasoconstriction, phentolamine, an alpha-adrenergic antagonist was adminis

38 such effects can be reduced by therapy with phentolamine, an alpha-adrenergic antagonist.

39 Phentolamine, an alpha-adrenergic blocking agent, preven

40 cine > yohimbine > RX821002 > MK912, whereas phentolamine and idazoxan were essentially neutral antag

41 Pretreatment with phentolamine and nitroglycerine increased transplanted c

42 , bosentan (20 mg/kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggestin

43 , bosentan (20 mg/kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggestin

44 The findings that phentolamine and propranolol increased plasma leptin con

45 ombined alpha- and beta-adrenergic blockade (phentolamine and propranolol) and after combined alpha-

46 a-adrenergic and beta-adrenergic antagonists phentolamine and propranolol, or 3) adrenergic blockade

47 tor blockade via intra-arterial infusions of phentolamine and propranolol, respectively.

48 se results indicated the orientation of both phentolamine and WB4101 in the alpha 1-AR binding pocket

49 seen in the alpha 1a-AR for two antagonists, phentolamine and WB4101.

50 -adrenergic (propranolol), alpha-adrenergic (phentolamine and yohimbine), and nitric oxide (NG-monome

51 ased by 21% (P<0.013) and 15% (P=0.004) with phentolamine and yohimbine, respectively.

52 to serotonin (methysergide), norepinephrine (phentolamine) and mu-opiates (naloxone).

53 before and after alpha-receptor inhibition (phentolamine) and then NPY Y1 receptor inhibition (BIBP

54 rol (saline), alpha-adrenoceptor inhibition (phentolamine), and combined alpha- and beta-adrenoceptor

55 ed using iontophoretic delivery of tyramine, phentolamine, and bretylium followed by a norepinephrine

56 nction in OZRs (adrenoreceptor blockade with phentolamine, antioxidant treatment with Tempol and thro

57 ipally by alpha-adrenergic receptors because phentolamine, but not propranolol, augmented the respons

58 utaneous depolarizations were antagonized by phentolamine, but not propranolol.

59 vascular conductance by 49.0 +/- 13.5% after phentolamine (compared to +16.8 +/- 7.0% in the control

60 eatment with the alpha-adrenergic antagonist phentolamine completely prevented loss of TAN, although

61 during 10% hypoxic exercise was greater with phentolamine (Delta306 +/- 43 ml min(-1)) vs. saline (De

62 e premortem cannulation, heparinization, and phentolamine despite current guidance in England to the

63 During hypoxaemia, fetuses treated with phentolamine did not elicit the pronounced femoral vasoc

64 Phentolamine during normoxia produced hypotension, tachy

65 -cholinergic (NANC) nerves with atropine and phentolamine (each 1 microM) were measured in the guinea

66 ery) alpha-adrenergic receptor blockade with phentolamine evoked greater increases in femoral blood f

67 of the alpha-adrenergic receptor antagonist phentolamine for only 30 min.

68 Subsequently, phentolamine further increased FBF to 11.7 +/- 1.6 ml (1

69 cose unclamped + intraportal propranolol and phentolamine hepatic alpha- and beta-adrenergic receptor

70 by the alpha-adrenergic receptor antagonist phentolamine (i.p. and i.t.) but not by the opioid recep

71 fect was abolished when co-administered with phentolamine (i.t.).

72 lol (IA PROP, 25 microg/min), intra-arterial phentolamine (IA PHEN, 12 microg/min per 100 ml forearm

73 milarly, non-selective alpha inhibition with phentolamine increased collateral conductance (242 +/- 5

74 Phentolamine increased the hepatic, splenic, and pulmona

75 Significantly less MA was observed with the phentolamine infusion 10-25 min after capsaicin injectio

76 e on the uninjected foot was seen during the phentolamine infusion compared with the saline infusion,

77 earance was not affected by cold exposure or phentolamine infusion.

78 anolol (IV PROP, 80 microg/min), intravenous phentolamine (IV PHEN, 500 microg/min), intra-arterial p

79 e treated with adrenergic receptor blockers (phentolamine, labetalol), a calcium channel blocker (nif

80 Prior administration of phentolamine, labetalol, and nitroglycerine prevented th

81 Animals were treated with phenylephrine, phentolamine, labetalol, and nitroglycerine.

82 o the donor 5 min before aortic cross clamp: phentolamine mesylate (PM) or hydralazine (H).

83 ent, 1.8 mL of study drug (containing 0.4 mg phentolamine mesylate or placebo) was injected per cartr

84 esis that local injection of the vasodilator phentolamine mesylate would shorten the duration of soft

85 ntagonist), yohimbine (alpha(2)-antagonist), phentolamine (non-selective alpha-antagonist) and bretyl

86 her the alpha-adrenergic receptor antagonist phentolamine nor the beta2-adrenergic receptor antagonis

87 ) after selective alpha-adrenergic blockade (phentolamine) of one forearm.

88 the lipolytic effect of the alpha-AR blocker phentolamine on adipocytes.

89 effect of alpha(1)-adrenoreceptor blockade (phentolamine) on supine SBP.

90 peated with fetal i.v. treatment with either phentolamine or a V1-receptor antagonist dissolved in sa

91 effects of fetal intravenous treatment with phentolamine or a vasopressinergic V1-receptor antagonis

92 of their corresponding receptor antagonists (phentolamine or methysergide).

93 application of alpha-adrenergic antagonists (phentolamine or phenoxybenzamine) increased spontaneous

94 anglionic action of guanethidine, but not by phentolamine or suramin.

95 ion of antagonists against NE (dibenamine or phentolamine) or ACh (atropine, alpha-bungarotoxin (alph

96 to +16.8 +/- 7.0% in the control arm without phentolamine, P < 0.05).

97 g intra-arterial infusions of normal saline, phentolamine (PHEN) and PHEN with angiotensin II (PHEN+A

98 Phentolamine, prazosin, or tetrodotoxin (1 microM) durin

99 ith the alpha-adrenergic receptor antagonist phentolamine prevented not only the elevation in mRNA le

100 dministered in the presence of bretylium and phentolamine prior to another bout of handgripping, litt

101 ons were not affected by naloxone, atropine, phentolamine, propranolol, methysergide, substance P ant

102 ivity persisted in the presence of atropine, phentolamine, propranolol, tetrodotoxin and Nomega-nitro

103 ine (Delta169 +/- 30 ml min(-1)) or combined phentolamine/propranolol (Delta213 +/- 25 ml min(-1); P

104 - 40 ml min(-1)) but was similar to combined phentolamine/propranolol (Delta450 +/- 43 ml min(-1)).

105 n subjects, administering yohimbine prior to phentolamine resulted in similar findings.

106 ure of BRIN-BD11 cells to either efaroxan or phentolamine selectively inhibited imidazoline-induced i

107 Two centers have used phentolamine to facilitate organ retrieval, with another

108 the extravasated vasopressors: intraosseous phentolamine, topical nitroglycerin ointment, and intraa

109 Importantly, phentolamine treatment inhibited early signaling events

110 ntagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator).

111 The phentolamine was well-tolerated and reduced the median d

112 ssessed via nonselective alpha-blockade with phentolamine) was significantly lower in older men.

113 inhibition versus alpha-adrenergic blockade (phentolamine), we found that the CCs accounted for appro

114 Methysergide and phentolamine were equipotent in reversing increases in S

115 histamine, serotonin, thyroid hormones, and phentolamine were without effect.

116 (-1), P<0.004) with propranolol, but neither phentolamine, yohimbine, or L-NMMA altered this response